Compare AU
Compare IOZ vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P Aussie 200 (IOZ) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IOZ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 695 | 63 |
Median incremental investment | $1,007.67 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,359.70 | $1,905.75 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
IOZ | DRUG | |
|---|---|---|
Strategy | The fund seeks to track the performance of the S&P/ASX 200 Accumulation Index before considering fees, expenses, and taxes. The index consists of the 200 largest Australian securities listed on the ASX. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | COMMONWEALTH BANK OF AUSTRALIA (9.67 %) BHP GROUP LTD (8.63 %) CSL LTD (5.87 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Financials (32.62 %) Materials (18.81 %) Health Care (8.87 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | Australia (94.85 %) United States (3.08 %) New Zealand (1.58 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.05 % | 0.57 % |
Key Summary
IOZ | DRUG | |
|---|---|---|
Issuer | iShares | BetaShares |
Tracking index | S&P ASX 200 | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.05 % | 0.57 % |
Price | $33.62 | $8.15 |
Size | $6.311 billion | $182.401 million |
10Y return | 48.11 % | N/A |
Annual distribution yield (5Y) | 5.36 % | 1.90 % |
Market | ASX | ASX |
First listed date | 09/12/2010 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IOZ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 695 | 63 |
Median incremental investment | $1,007.67 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,359.70 | $1,905.75 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
IOZ | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IOZ | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |